e-learning
resources
Milan 2017
Sunday, 10.09.2017
Clinical points to ponder in asthma
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Economic costs of severe asthma in omalizumab-treated patients. FENOMA Study
A. Gomez-Bastero (Sevilla, Spain)
Source:
International Congress 2017 – Clinical points to ponder in asthma
Session:
Clinical points to ponder in asthma
Session type:
Thematic Poster
Number:
636
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Gomez-Bastero (Sevilla, Spain). Economic costs of severe asthma in omalizumab-treated patients. FENOMA Study. 636
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Cost effectiveness of omalizumab in Swedish asthma patients
Source: Eur Respir J 2006; 28: Suppl. 50, 441s
Year: 2006
Clinical characteristics and burden of illness in a cohort of severe asthma patients
Source: International Congress 2016 – Asthma: treatment, disease control, and quality of life
Year: 2016
Short-term evaluation of a remote patient support program in patients with COPD and frequent exacerbations. ESOPO study
Source: International Congress 2015 – Asthma and COPD: overlap and exacerbations
Year: 2015
Cost of asthma in patients treated with national asthma guideline in Turkey
Source: Eur Respir J 2003; 22: Suppl. 45, 481s
Year: 2003
Real-world outcomes in patients receiving omalizumab for allergic asthma in India: Analysis by baseline IgE level
Source: Annual Congress 2013 –Treatment of asthma
Year: 2013
Treatment eligibility of mepolizumab-treated severe asthma patients in clinical practice
Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma
Year: 2019
Dupilumab reduces severe exacerbation-related costs among asthma patients: Results from a phase 2b trial
Source: International Congress 2016 – How the increasing complexity of chronic care management challenges ethics and costs in our healthcare system
Year: 2016
Impact of omalizumab in patients with severe asthma
Source: Annual Congress 2009 - Aspects of uncontrolled asthma
Year: 2009
Health care costs in COPD patients with severe respiratory failure: a prospective analysis
Source: Annual Congress 2009 - Organisation of care for individuals with chronic respiratory disease
Year: 2009
X-Tab: Non-interventional study to assess patient-related mid-term outcomes of omalizumab therapy in severe allergic asthmatic patients
Source: International Congress 2016 – Phenotyping and monitoring airway diseases
Year: 2016
Incidence and severity of acute exacerbations among women enrolled in an asthma management program during pregnancy: A prospective study of 1.283 pregnancies
Source: International Congress 2016 – Best abstracts in asthma and COPD
Year: 2016
Effectiveness of omalizumab in Greek patients with severe allergic asthma (SAA): The SMILE study
Source: International Congress 2016 – Asthma points to ponder
Year: 2016
Effectiveness of montelukast on asthma control in infants: A claims data study
Source: International Congress 2015 – Treatment and control of respiratory disease
Year: 2015
Effectiveness of self-treatment of exacerbations in COPD patients: Two-year follow-up of the COPE-II study
Source: International Congress 2014 – Best abstracts in rehabilitation and chronic care (sponsored by MOTEK Medical)
Year: 2014
The impact of the addition of omalizumab on the utilization of healthcare resources by severe persistent asthma patients
Source: Annual Congress 2013 –Asthma drugs: new findings
Year: 2013
Real-life effectiveness of omalizumab in difficult-to-treat
versus
severe asthma: a national cohort study in Belgium
Source: ERJ Open Res, 5 (4) 00253-2018; 10.1183/23120541.00253-2018
Year: 2019
Cost analysis for patients with severe asthma receiving omalizumab treatment
Source: International Congress 2019 – Clinical aspects of airway diseases
Year: 2019
Risk factors for self-reported hospitalizations among stable outpatients with COPD
Source: Annual Congress 2013 –The best posters in chronic care
Year: 2013
Bronchial thermoplasty in patients with very severe asthma: Safety and clinical outcomes
Source: International Congress 2016 – Airway stenting and ablation
Year: 2016
Clinical trials for elderly patients with multiple diseases (CHROMED): A pilot study
Source: International Congress 2014 – The assessment of comorbidities
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept